Stay updated with breaking news from Arcus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the... | June 11, 2023
Updated data from ARC-7, the randomized Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, will be presented in a special ASCO plenary series rapid abstract update session... | May 17, 2023
– Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases – – Expanded Research Collaboration May Result in up to... | May 15, 2023
Arcus Biosciences, Inc. (NYSE:RCUS – Get Rating) – Investment analysts at Wedbush dropped their Q2 2023 earnings per share estimates for Arcus Biosciences in a report issued on Wednesday, May 10th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($1.23) per share for the quarter, down from their prior estimate […]
Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. The third dose-escalation cohort of ARC-20 for AB521, a... | May 9, 2023